Biotech News

Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results

Absci Corporation (ABSI)Absci CorporationEarnings

ABS-201™ HEADLINE™ trial progressing on track; 13-week interim proof-of-concept data for pattern hair loss (PHL) anticipated next month Announced preliminary details for Phase 2 STORYLINE™ trial of ABS-201 for endometriosis Appointed former Galderma executive Gerry Muhle as Chief Commercial Officer

Related news

Absci Corporation

AI-Enabled Biologic Design Absci combines generative artificial intelligence with high-throughput synthetic biology to design and validate novel biologics. Its integrated platform repeatedly feeds laboratory results back into computational models. ABS-201 ABS-201 is a long-acting antibody against the prolactin receptor. Its...

Recent company news

Stock data

Close
8.16 USD
Market cap
990M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States